Core Viewpoint - Sichuang Medical Technology Co., Ltd. is under investigation for suspected fraudulent issuance of securities, with the case currently in the police investigation stage [1] Group 1: Investigation and Legal Issues - The investigation is closely related to previous financial fraud cases, where Sichuang Medical inflated revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflated revenue by 60.96 million yuan and profits by 52.37 million yuan in 2020, accounting for 20.03% and 56.81% of the respective profits [2] - The fraudulent data was included in the annual reports for 2019 and 2020, which were used as important evidence for the issuance of 817 million yuan in convertible bonds in 2021 [3] - The company has faced significant penalties, including a fine of 85.7 million yuan and a 10-year market ban for the former chairman [3] Group 2: Corporate Restructuring - In response to regulatory pressure, the company has made significant adjustments to its ownership structure and business layout, including the resignation of the former chairman and the transfer of control to the Cangnan County Finance Bureau [3] - The company has also divested its subsidiary, Medical Technology Co., which was the main platform for the financial fraud, and has shifted its focus to the Internet of Things sector [4] Group 3: Financial Performance - The company has reported continuous losses, with net profits of -878 million yuan, -874 million yuan, -502 million yuan, and -19.56 million yuan for the years 2022 to 2025 Q1, with a 71.14% reduction in losses for Q1 2025 compared to the same period last year [4] - The company claims that its financial situation has improved since the entry of state-owned capital, with a reduction in losses since 2024 [4] Group 4: Regulatory Environment - The capital market has intensified its crackdown on financial fraud and fraudulent issuance, with a focus on establishing a comprehensive accountability mechanism involving administrative, civil, and criminal responsibilities [5][6] - The ongoing investigation into Sichuang Medical is closely monitored by investors, with the company actively cooperating with the police and preparing compensation plans for affected investors [6]

Core Viewpoint - The company Sichuan Medical Technology Co., Ltd. (思创医惠) is under criminal investigation for financial fraud, following previous administrative penalties related to falsified financial statements [1][4][5]. Group 1: Investigation and Legal Actions - The company received a notification from the Hangzhou Public Security Bureau regarding the collection of evidence related to a fraud case involving securities issuance [1][4]. - The investigation focuses on past financial data and is linked to an earlier administrative penalty issued by the Zhejiang Securities Regulatory Commission [3][5]. - The Zhejiang Securities Regulatory Commission found that the company inflated its revenue by CNY 34.93 million and profits by CNY 33.02 million in 2019, which constituted 20.03% of the total profit for that period [6][7]. Group 2: Financial Performance and Adjustments - In 2024, the company reported a revenue of CNY 690.77 million, a decrease of 31.33% compared to 2023, and a net loss of CNY 501.51 million, which is a 42.64% reduction in losses year-on-year [11][12]. - The company has undergone significant restructuring, including the resignation of its former chairman and the sale of its subsidiary, which was the main platform for the financial fraud [9][10]. - The company is shifting its focus from smart medical services to the Internet of Things (IoT) business, aiming to enhance its growth engine [10]. Group 3: Investor Relations and Future Plans - The company is actively communicating with investors regarding potential compensation plans and is coordinating with courts on specific details related to investor lawsuits [8]. - A strategic cooperation framework has been established with the Cangnan County government to support various aspects of business development [9].

以下文章来源于e公司 ，作者证券时报 叶玲珍 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 思创医惠所涉案件，在此前的公告中或可见端倪。 2022年10月28日，思创医惠因涉嫌信息披露违法违规，被中国证监会立案调查。2024年1月8日，前述事项已查明，公司及相关当事人收到浙江证监局出具的《行政 处罚决定书》。 8月15日晚间，思创医惠（300078）发布公告，公司于8月14日收到杭州市公安局《调取证据通知书》。据悉，杭州市公安局侦办的公司等涉嫌欺诈发行证券案 需调取有关证据材料。 截至目前，案件处于公安机关侦查阶段，尚未有明确结论。公司表示，后续将积极配合调查取证工作，并根据案件进展履行信息披露义务。 针对前述违法行为，浙江证监局决定对思创医惠责令改正，给予警告，并处以8570万元罚款；同时对时任董事长、总经理章笠中给予警告，并处以750万元罚款，并 采取10年市场禁入措施。 思创医惠此前主要经营商业智能及智慧医疗业 ...

Group 1 - The core issue involves a fraud investigation against the company by the Hangzhou Public Security Bureau regarding the alleged fraudulent issuance of securities [1] - The company has previously been under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to administrative penalties [3] - The company was found to have fabricated significant false information in its public bond issuance documents, resulting in inflated revenue and profits for the years 2019 and 2020 [3][4] Group 2 - The company was penalized with a fine of 85.7 million yuan and its former chairman and general manager received individual fines and a 10-year market ban [5] - The company has faced significant revenue declines and continuous losses due to intense industry competition and business adjustments [5] - The company completed the divestiture of its 100% stake in its subsidiary, Medical Technology Co., Ltd., in August 2025 [5]

*ST高鸿公告，公司股票连续三个交易日（2025年8月11日、2025年8月12日、2025年8月13日）收盘价 格跌幅累计超过12%。公司被中国证券监督管理委员会立案调查，根据《行政处罚事先告知书》的认 定，公司2020年非公开发行股票构成欺诈发行、2015年至2023年年度报告存在虚假记载，将触及《深圳 证券交易所股票上市规则》第9.5.1条第一项、第9.5.2条第一款第（六）项规定的重大违法强制退市情 形，可能被实施重大违法强制退市。公司股票自2025年8月11日起被深圳证券交易所叠加实施退市风险 警示。 ...

Core Viewpoint - The article discusses the legal actions taken against Gel Software and other parties involved in the fraudulent issuance and information disclosure violations related to Zeda Yisheng Technology Co., Ltd, highlighting the financial implications and the ongoing litigation process [2][4]. Group 1: Legal Proceedings - On August 12, Gel Software announced that it, along with 38 other defendants, is being sued for a total of approximately 37,227.26 million yuan across three cases related to fraudulent issuance and information disclosure violations [2]. - The three cases involve claims of 12,345.51 million yuan, 21,533.20 million yuan, and 3,348.55 million yuan respectively, with the total amount claimed being 37,227.26 million yuan [2]. - The plaintiffs include Dongxing Securities, Tianjian Accounting Firm, and Beijing Kangda Law Firm, all of which were intermediaries in Zeda Yisheng's initial public offering [4]. Group 2: Background and Financial Impact - In April 2023, Zeda Yisheng was penalized by the China Securities Regulatory Commission for fraudulent issuance and information disclosure violations, leading to investor lawsuits against Zeda Yisheng and its intermediaries [4]. - Following the penalties, Dongxing Securities, Tianjian Accounting, and Kangda Law Firm collectively paid approximately 493 million yuan to investors and the regulatory authority, prompting them to seek recovery of these costs through litigation against other involved parties [4]. - Gel Software's involvement stems from business transactions with Zeda Yisheng in 2018 and 2020, which were later found to lack commercial substance during a self-examination process [4].

Group 1 - Company *ST Gao Hong (000851.SZ) has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a trading halt with shares dropping to 2.1 yuan and over 4 million shares on hold [1] - The CSRC's notice indicates that the company engaged in fraudulent issuance of shares during its non-public offering in 2020, and its annual reports from 2015 to 2023 contain false records, potentially leading to mandatory delisting [1] - Investigations revealed that *ST Gao Hong inflated its revenue and profits through fictitious trade activities, resulting in a total inflated revenue of 19.876 billion yuan and inflated profit of 76.2259 million yuan from 2015 to 2023 [1] Group 2 - The CSRC plans to impose a fine of 160 million yuan on the responsible parties and an additional 7 million yuan on third parties involved in the fraudulent activities [1]

又一家上市公司因财务造假遭证监会重罚，公司及9名责任人连同配合造假的第三方被处以总计1.6亿元 的天价罚单。 8月8日晚间，证监会公布对深交所主板上市公司大唐高鸿网络股份有限公司（以下简称"*ST高鸿"或"高 鸿股份"）涉嫌信息披露违法违规行为依法作出行政处罚事先告知。 证监会查明，*ST高鸿长期开展无商业实质的笔记本电脑等"空转""走单"业务，大幅虚增收入和利润， 违反证券法律法规。证监会拟对相关责任主体罚款1.6亿元，对配合造假的第三方罚款700万元。同时， *ST高鸿涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。 证监会下发的《行政处罚事先告知书》(以下简称《告知书》)显示，2015—2023年，高鸿股份通过笔记 本电脑虚假贸易业务等方式虚增营收和利润，合计虚增营收198.76亿元，虚增利润总额超7622.59万元。 值得注意的是，在6月"越博动力案"中，监管层首次对两名配合造假第三方主体进行了直接处罚。不到 两个月，监管对配合上市公司造假的第三方重罚再添一例。 受访人士表示，这是监管层"追首恶"与"打帮凶"多措并举的体现，依托立体化追责体系严惩全链条造假 主体。 欺诈发行叠加财务造假 202 ...

文/梧桐兄弟 8月8日，*ST高鸿（000851）披露了关于收到中国证券监督管理委员会《行政处罚事先告知书》及重大违法强制退市风险提示公告，公司于2025年8月8日收到中国 证监会下发的《行政处罚事先告知书》。 根据《告知书》认定的事实，公司 2020 年非公开发行股票构成欺诈发行、 2015 年至 2023 年年度报告存在虚假记载，将触及《深圳证券交易所股票上市规则》第 9.5.1 条第一项、第 9.5.2 条第一款第（六）项规定的重大违法强制退市情形， 可能被实施重大违法强制退市。 值得注意的是，*ST高鸿一名董事配偶并不在上市公司任职，但 其明知涉案笔记本电脑虚假贸易业务对于高鸿股份而言属于"空转""走单"贸易业务，将导致高鸿股 份业绩虚高，仍主动联系高鸿科技开展合作，将其纳入该贸易业务链条，其行为与高鸿股份 2015 年至 2021 年信息披露违法行为构成共同违法，应当受到处罚。 根据《告知书》披露，高鸿股份及相关人员违法事实情况主要如下： 一、高鸿股份通过参与、组织开展虚假贸易业务的方式虚增收入和利润，2015 年至 2023 年年度报告存在虚假记载 (一)高鸿股份通过参与笔记本电脑虚假贸易业务的方 ...

证券代码：000851 证券简称：*ST 高鸿 公告编号：2025-085 大唐高鸿网络股份有限公司 关于收到中国证券监督管理委员会《行政处罚事先告知书》及 重大违法强制退市风险提示公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 特别提示： 规，被中国证券监督管理委员会(以下简称"中国证监会")立案调查。公司于 2025 年 8 月 8 日收到中国证监会下发的《行政处罚事先告知书》(以下简称"《告知 书》")。根据《告知书》认定的事实，公司 2020 年非公开发行股票构成欺诈发 行、2015 年至 2023 年年度报告存在虚假记载，将触及《深圳证券交易所股票上 市规则》第 9.5.1 条第一项、第 9.5.2 条第一款第（六）项规定的重大违法强制 退市情形，可能被实施重大违法强制退市。 公司触及重大违法强制退市情形，公司股票将被终止上市。 大唐高鸿网络股份有限公司（以下简称"公司"）于 2024 年 7 月 31 日于巨 潮资讯网披露了《关于收到中国证券监督管理委员会立案告知书的公告》（公告 编号：2024-099），因公司涉嫌信息披露违法违规，根据《中 ...